Vitamin D and prostate cancer

Larisa Nonn; Kirsten Krieger; Clayton Yates; Moray J. Campbell

doi:10.1016/B978-0-323-91338-6.00041-0

Vitamin D and prostate cancer

Larisa Nonn, Kirsten Krieger, Clayton Yates, Moray J. Campbell

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Epidemiologic studies have shown protective effects of 25(OH)D3 status on prostate cancer risk and mortality. Herein, we discuss the actions of vitamin D metabolites in the prostate and the efforts to leverage these actions to prevent and treat prostate cancer. The prostate expresses vitamin D metabolism enzymes, expresses vitamin D receptor, and is responsive to vitamin D metabolites. We present key pathways and genes regulated by 1,25(OH)2D3 in prostate cells and tissues. We discuss the anticancer effects of vitamin D metabolites in preclinical models and clinical trials. Studies that include a diverse cohort are highlighted as men of African descent have a dual disparity in 25(OH)D3 deficiency and prostate cancer mortality. Lastly, we offer perspectives on the challenges in this field and opportunities for future work.

Original language	English (US)
Title of host publication	Feldman and Pike's Vitamin D
Subtitle of host publication	Volume Two: Disease and Therapeutics
Publisher	Elsevier
Pages	917-935
Number of pages	19
ISBN (Electronic)	9780323913386
ISBN (Print)	9780323913393
DOIs	https://doi.org/10.1016/B978-0-323-91338-6.00041-0
State	Published - Jan 1 2023
Externally published	Yes

Keywords

Androgens
Health disparities
Inflammation
Prostate cancer

ASJC Scopus subject areas

General Arts and Humanities

Access to Document

10.1016/B978-0-323-91338-6.00041-0

Cite this

@inbook{1af08c3da26042cc9b455ec3bb02ea5c,

title = "Vitamin D and prostate cancer",

abstract = "Epidemiologic studies have shown protective effects of 25(OH)D3 status on prostate cancer risk and mortality. Herein, we discuss the actions of vitamin D metabolites in the prostate and the efforts to leverage these actions to prevent and treat prostate cancer. The prostate expresses vitamin D metabolism enzymes, expresses vitamin D receptor, and is responsive to vitamin D metabolites. We present key pathways and genes regulated by 1,25(OH)2D3 in prostate cells and tissues. We discuss the anticancer effects of vitamin D metabolites in preclinical models and clinical trials. Studies that include a diverse cohort are highlighted as men of African descent have a dual disparity in 25(OH)D3 deficiency and prostate cancer mortality. Lastly, we offer perspectives on the challenges in this field and opportunities for future work.",

keywords = "Androgens, Health disparities, Inflammation, Prostate cancer",

author = "Larisa Nonn and Kirsten Krieger and Clayton Yates and Campbell, {Moray J.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-91338-6.00041-0",

language = "English (US)",

isbn = "9780323913393",

pages = "917--935",

booktitle = "Feldman and Pike's Vitamin D",

publisher = "Elsevier",

}

TY - CHAP

T1 - Vitamin D and prostate cancer

AU - Nonn, Larisa

AU - Krieger, Kirsten

AU - Yates, Clayton

AU - Campbell, Moray J.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Epidemiologic studies have shown protective effects of 25(OH)D3 status on prostate cancer risk and mortality. Herein, we discuss the actions of vitamin D metabolites in the prostate and the efforts to leverage these actions to prevent and treat prostate cancer. The prostate expresses vitamin D metabolism enzymes, expresses vitamin D receptor, and is responsive to vitamin D metabolites. We present key pathways and genes regulated by 1,25(OH)2D3 in prostate cells and tissues. We discuss the anticancer effects of vitamin D metabolites in preclinical models and clinical trials. Studies that include a diverse cohort are highlighted as men of African descent have a dual disparity in 25(OH)D3 deficiency and prostate cancer mortality. Lastly, we offer perspectives on the challenges in this field and opportunities for future work.

AB - Epidemiologic studies have shown protective effects of 25(OH)D3 status on prostate cancer risk and mortality. Herein, we discuss the actions of vitamin D metabolites in the prostate and the efforts to leverage these actions to prevent and treat prostate cancer. The prostate expresses vitamin D metabolism enzymes, expresses vitamin D receptor, and is responsive to vitamin D metabolites. We present key pathways and genes regulated by 1,25(OH)2D3 in prostate cells and tissues. We discuss the anticancer effects of vitamin D metabolites in preclinical models and clinical trials. Studies that include a diverse cohort are highlighted as men of African descent have a dual disparity in 25(OH)D3 deficiency and prostate cancer mortality. Lastly, we offer perspectives on the challenges in this field and opportunities for future work.

KW - Androgens

KW - Health disparities

KW - Inflammation

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85179203685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179203685&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-91338-6.00041-0

DO - 10.1016/B978-0-323-91338-6.00041-0

M3 - Chapter

AN - SCOPUS:85179203685

SN - 9780323913393

SP - 917

EP - 935

BT - Feldman and Pike's Vitamin D

PB - Elsevier

ER -

Vitamin D and prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this